Chargement en cours...
Cardiac Myosin Activation for the Treatment of Systolic Heart Failure
Left ventricular systolic dysfunction is the hallmark pathology in heart failure with reduced ejection fraction. Increasing left ventricular contractility with beta-adrenergic receptor agonists, phosphodiesterase-3 inhibitors, or levosimendan has failed to improve clinical outcomes and, in some situ...
Enregistré dans:
| Publié dans: | J Cardiovasc Pharmacol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7779665/ https://ncbi.nlm.nih.gov/pubmed/33165138 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FJC.0000000000000929 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|